Cora:
As a long-acting injectable medicine, ARISTADA provides patients, clinicians and families the certainty that patients receive medication for this serious brain disorder.
Lorina:
Alkermes is preparing to launch ARISTADA immediately.
Macy:
ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection.
Collette:
This, though usually a good sign, quickly became overshadowed by the negative indicators, such as low scores, increasing shares outstanding, and bad financials.
Lakia:
At a first glance, the stock looks promising, growing consistently over the past three years.
Marjorie:
The more fields I tested against ALKS, the more I grew to dislike the stock.
Jessika:
ALKS scores a 2 out of 7, and its score has been steadily decreasing over the past three years.
Karolyn:
This score, a score out of 7, helps to indicate whether a company has a strong past and has the probability of going up, even slightly, in the future.
Luisa:
This past year, however, the company fell backwards, only having $11 million in cash flow and ultimately having a negative FCF/share.
Angelo:
At this point, the prospects for this company looked good and the share price began to surge.
Alkermes (NASDAQ:ALKS)
//stockhand.net/us/?q=nasdaq%3Aalks&id=722472
No comments:
Post a Comment